A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics
A Randomized, Double-blind, Placebo-controlled, Sequential Parallel Group, Multiple Ascending Doses Study Following Intravenous Administration in Healthy Chinese Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of HNC042
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Jiang Yuting
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- volunteers can communicate well with the investigator, understand and comply with the relevant requirements of the study, understand and sign the informed consent
- Healthy adult male or female volunteers, age 18-65 years,
- BMI between 19-26 kg/m2,and male body weight not less than 50.0kg,female body weight not less than 45.0kg .
- volunteers with normal renal function
Exclusion Criteria:
- Any condition that might interfere with the procedures or tests in this study
- Drug or alcohol abuse
- Smoking
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: HNC042
HNC4042 for injection,freeze-dried powder,multiple ascending doses, Intravenous route
|
HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, doses: 300mg to 1200mg
|
|
Placebo Comparator: Placebo
Placebo, multiple ascending doses, Intravenous route
|
Placebo , Intravenous route , multiple ascending doses
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of subjects with abnormal vital signs
Time Frame: Between screening and 15 days after the last dose
|
To evaluate the safety and tolerability of HNC042 in comparison with placebo after multiple intravenous dose in healthy Chinese subjects in terms of abnormal vital signs
|
Between screening and 15 days after the last dose
|
|
Number of subjects with abnormal laboratory
Time Frame: Between screening and 15 days after the last dose
|
To evaluate the safety and tolerability of HNC042 in comparison with placebo after multiple intravenous dose in healthy Chinese subjects in terms of abnormal laboratory
|
Between screening and 15 days after the last dose
|
|
Number of subjects with abnormal electrocardiogram
Time Frame: Between screening and 15 days after the last dose
|
To evaluate the safety and tolerability of HNC042 in comparison with placebo after multiple intravenous dose in healthy Cjinese subjects in terms of abnormal electrocardiogram
|
Between screening and 15 days after the last dose
|
|
Number of subjects with abnormal physical examination
Time Frame: Between screening and 15 days after the last dose
|
To evaluate the safety and tolerability of HNC042 in comparison with placebo after multiple intravenous dose in healthy Cjinese subjects in terms of abnormal physical examination
|
Between screening and 15 days after the last dose
|
|
Number of subjects with adverse reactions at injection site
Time Frame: Between screening and 15 days after the last dose
|
To evaluate the safety and tolerability of HNC042 in comparison with placebo after multiple intravenous dose in healthy Cjinese subjects in terms of adverse reactions at injection site
|
Between screening and 15 days after the last dose
|
|
Number of subjects with adverse events
Time Frame: Between screening and 15 days after the last dose
|
To evaluate the safety and tolerability of HNC042 in comparison with placebo after multiple intravenous dose in healthy Cjinese subjects in terms of adverse events
|
Between screening and 15 days after the last dose
|
|
Number of subjects with clinical symptoms
Time Frame: Between screening and 15 days after the last dose
|
To evaluate the safety and tolerability of HNC042 in comparison with placebo after multiple intravenous dose in healthy Cjinese subjects in terms of clinical symptoms
|
Between screening and 15 days after the last dose
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pharmacokinetics of HNC042 in plasma: Cmax
Time Frame: Between Day 1 to 7 days
|
To characterize the pharmacokinetic parameters:Cmax of HNC042 after the the first day administer .
|
Between Day 1 to 7 days
|
|
Pharmacokinetics of HNC042 in plasma: Tmax
Time Frame: Between Day 1 to 7 days
|
To characterize the pharmacokinetic parameters:Tmax of HNC042 after the the first day administer .
|
Between Day 1 to 7 days
|
|
Pharmacokinetics of HNC042 in plasma: AUC0-last
Time Frame: Between Day 1 to 7 days
|
To characterize the pharmacokinetic parameters:AUC0-last of HNC042 after the the first day administer .
|
Between Day 1 to 7 days
|
|
Pharmacokinetics of HNC042 in plasma: AUC0-∞
Time Frame: Between Day 1 to 7 days
|
To characterize the pharmacokinetic parameters: AUC0-∞ of HNC042 after the the first day administer .
|
Between Day 1 to 7 days
|
|
Pharmacokinetics of HNC042 in plasma:t1/2
Time Frame: Between Day 1 to 7 days
|
To characterize the pharmacokinetic parameters: t1/2 of HNC042 after the the first day administer .
|
Between Day 1 to 7 days
|
|
Pharmacokinetics of HNC042 in plasma:MRT
Time Frame: Between Day 1 to 7 days
|
To characterize the pharmacokinetic parameters: MRT of HNC042 after the the first day administer .
|
Between Day 1 to 7 days
|
|
Pharmacokinetics of HNC042 in plasma:CL
Time Frame: Between Day 1 to 7 days
|
To characterize the pharmacokinetic parameters:CL of HNC042 after the the first day administer .
|
Between Day 1 to 7 days
|
|
Pharmacokinetics of HNC042 in plasma:Vd
Time Frame: Between Day 1 to 7 days
|
To characterize the pharmacokinetic parameters:Vd of HNC042 after the the first day administer .
|
Between Day 1 to 7 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Lu Xiang, MD, Sir Run Run Hospital, Nanjing Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- HNC042-102
- ZBD1042-CSP01 (Other Grant/Funding Number: Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.